Orexin-narcolepsy research earns prestigious Lasker Award
The scientific work that uncovered the role of orexin in narcolepsy has been recognized with a Lasker Award, following a Breakthrough Prize. The research journey involved studies in mice, dogs, and even the flu virus, leading to a deeper understanding of the sleep disorder. This award underscores the importance of basic research in translating to clinical insights.
The award follows a prior Breakthrough Prize, underscoring the cumulative weight of this specific research trajectory. It specifically honors the foundational discoveries that linked the neuropeptide orexin directly to the sleep disorder narcolepsy.
The investigative path was notably broad, spanning studies in mice, dogs, and even the flu virus. This diverse experimental approach ultimately clarified the biological mechanisms behind narcolepsy, illustrating how varied basic research avenues can converge on a single, profound clinical understanding.
This recognition could bolster investment in orexin-based therapeutics, potentially leading to more targeted treatments for narcolepsy patients who currently rely on symptom management. It may also encourage broader funding for fundamental research, as the award highlights how seemingly unrelated studies—from viral infections to animal genetics—can yield transformative clinical insights. Ultimately, patients with sleep disorders may see improved options if this momentum translates into new drug development pipelines.